Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty

Naratuximab emtansine

Catalog No. T9901A-223Cas No. 1607824-64-5
Alias IMGN529, Debio 1562

Naratuximab emtansine (IMGN529) is a CD37-targeted antibody-drug conjugate (ADC) composed of a humanized IgG1 monoclonal antibody linked to the microtubule-disrupting agent DM1. This compound demonstrates high affinity and specificity to CD37, facilitating the internalization, processing, and intracellular release of DM1. The functional activity of DM1 enables it to induce cell cycle arrest and apoptosis by disrupting microtubule assembly.

Naratuximab emtansine

Naratuximab emtansine

Catalog No. T9901A-223Alias IMGN529, Debio 1562Cas No. 1607824-64-5
Naratuximab emtansine (IMGN529) is a CD37-targeted antibody-drug conjugate (ADC) composed of a humanized IgG1 monoclonal antibody linked to the microtubule-disrupting agent DM1. This compound demonstrates high affinity and specificity to CD37, facilitating the internalization, processing, and intracellular release of DM1. The functional activity of DM1 enables it to induce cell cycle arrest and apoptosis by disrupting microtubule assembly.
Pack SizePriceAvailabilityQuantity
1 mgInquiryBackorder
5 mgInquiryBackorder
Bulk & Custom
Add to Cart
Questions
View More
Contact us for more batch information
Resource Download
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.

Product Introduction

Bioactivity
Description
Naratuximab emtansine (IMGN529) is a CD37-targeted antibody-drug conjugate (ADC) composed of a humanized IgG1 monoclonal antibody linked to the microtubule-disrupting agent DM1. This compound demonstrates high affinity and specificity to CD37, facilitating the internalization, processing, and intracellular release of DM1. The functional activity of DM1 enables it to induce cell cycle arrest and apoptosis by disrupting microtubule assembly.
In vitro
Naratuximab emtansine (IMGN529) (0.125 nM, 24 h) administered alone can induce activation of caspases 3/7 in DLBCL cell lines, an effect significantly enhanced by the presence of rituximab (2 nM), which further induces an increase in cleaved PARP levels. Additionally, Naratuximab emtansine (IMGN529) (0-3 ng/mL) demonstrates dose-dependent antibody-dependent cell-mediated cytotoxicity (ADCC) activity in U-2932 and SU-DHL-4 cell lines.
In vivo
A single treatment of Naratuximab emtansine (IMGN529) at a dosage of 10 mg/kg (administered as a one-time injection) showed no activity against U-2932 tumors alone. However, when combined with rituximab, there was a significant enhancement in antitumor activity. Throughout the study, no noticeable toxicity or weight loss was observed in female U2932 CB.17-SCID mice.
AliasIMGN529, Debio 1562
Chemical Properties
Cas No.1607824-64-5
Storage & Solubility Information
StoragePowder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice.

Calculator

  • Molarity Calculator
  • Dilution Calculator
  • Reconstitution Calculator
  • Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
TargetMol | Animal experimentsFor example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . TargetMol | Animal experiments A total of 10 animals were administered, and the formula you used is 5% TargetMol | reagent DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。
Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSOTargetMol | reagent (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
Preparation method for in vivo formula: Take 50 μL DMSOTargetMol | reagent main solution, add 300 μLPEG300TargetMol | reagent mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2OTargetMol | reagent mix well and clarify
For Reference Only. Please develop an appropriate dissolution method based on your laboratory animals and route of administration.
1 Enter information below:
mg/kg
g
μL
2 Enter the in vivo formulation:
% DMSO
%
%Tween 80
%ddH2O

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Related Tags: buy Naratuximab emtansine | purchase Naratuximab emtansine | Naratuximab emtansine cost | order Naratuximab emtansine | Naratuximab emtansine in vivo | Naratuximab emtansine in vitro